44 results about "Vaccinia" patented technology

The present invention relates to a primer set, composition, kit for the detection of vaccinia virus for the detection and quantification of vaccinia virus and an analysis method using the same, and the primer set for the detection of vaccinia virus has a shorter analysis period and superior sensitivity and specificity compared to the conventional virus quantitation method, so that when real-time PCR applied to such a primer set is performed, it is possible to detect and quantify vaccinia virus more quickly and accurately in real time.

Exemplary methods, compositions, kits and uses thereof for treating neoplasia are provided. For example, a method can be provided for treating neoplasia in a subject, including administering to the subject a VRK2 (vaccinia-related kinase 2) inhibitor, alone or in combination with an inhibitor of Programmed cell death receptor-1 (PD-1). The exemplary methods, compositions and kits may improve cancer immunotherapy.

The present invention relates to an oncolytic vaccinia virus and viral vectors for use in the treatment of cancer wherein the virus consists of at least three vaccinia virus promoters positioned in the same orientation.

Described herein are methods and compositions for treating a disease, e.g. cancer (including solid tumors), using glial cells (e.g. microglia cells and / or astrocytes) and / or macrophages (e.g., CNS-associated macrophages) infected with an oncolytic virus (e.g., vaccinia virus). The methods and compositions provided herein demonstrate a synergistic anti-cancer effect.

Provided herein is a method for efficiently capping RNA in vitro. In some embodiments the capping reaction may be done at high temperature using Vaccinia capping enzyme or a variant thereof. In other embodiments, the capping reactions may comprise a capping enzyme from a large virus of amoeba, e.g., Faustovirus, mimivirus or moumouvirus, or a variant thereof. Compositions and kits for practicing the method are also provided.

This invention relates to the fields of biotechnology and targeted therapy, specifically to a recombinant construct, a recombinant oncolytic virus, its construction method, and its applications. The recombinant oncolytic virus CD19 BIKE is prepared by inserting exogenous genes for CD16 and CD19 into the genome of an oncolytic vaccinia virus. The antibodies secreted by this recombinant virus can not only bridge NK cells and CD19-positive B-cell lymphoma cells, increasing the contact between NK cells and tumor cells and their accumulation within tumor tissue, but also synergize with the tumor-lysing effect of the oncolytic virus, breaking down the stromal barrier, reshaping the tumor microenvironment, and enhancing therapeutic efficacy.

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.

To provide a method for efficiently capping RNA in vitro.SOLUTION: In some embodiments, the capping reaction can be done at high temperature using Vaccinia capping enzyme or variants thereof. In other embodiments, the capping reaction may comprise capping enzymes from amoebic large viruses, such as Faust, Mimivirus, or Moumouvirus, or variants thereof. Compositions and kits for practicing the methods are also provided.SELECTED DRAWING: None

Provided herein is a method for efficiently capping RNA in vitro. In some embodiments the capping reaction may be done at high temperature using Vaccinia capping enzyme or a variant thereof. In other embodiments, the capping reactions may comprise a capping enzyme from a large virus of amoeba, e.g., Faustovirus, mimivirus or moumouvirus, or a variant thereof. Compositions and kits for practicing the method are also provided.

The invention belongs to the technical field of biological medicines, and provides a heat stress protein HSP70 inhibitor and application thereof in preparation of antitumor drugs. Experiments prove that the heat stress protein HSP70 inhibitor can enhance the replication capacity of oncolytic viruses in tumor cells and enhance the anti-tumor immune activation capacity at the same time; the invention further proves that the oncoVV-shHSP70 can effectively inhibit the expression of the HSP70 protein, so that the survival rate of various cancer cells can be obviously reduced, the effect is obviously superior to that of a control virus oncoVV only lacking the TK gene, and meanwhile, the oncoVV-shHSP70 can promote the infiltration of CD8 < + >-T cells in tumor tissues. The HSP70 inhibitor can be used for preparing an anti-tumor virus drug, particularly, the HSP70 inhibitor and the vaccinia virus are recombined into a recombinant vector, the advantages of the HSP70 inhibitor and the vaccinia virus can be combined, a new target spot is provided for virus treatment of tumors, and the HSP70 inhibitor has a wide clinical application prospect.

Exemplary methods, compositions, kits and uses thereof for treating neoplasia are provided. For example, a method can be provided for treating neoplasia in a subject, including administering to the subject a VRK2 (vaccinia-related kinase 2) inhibitor, alone or in combination with an inhibitor of Programmed cell death receptor-1 (PD-1). The exemplary methods, compositions and kits may improve cancer immunotherapy.

The present invention relates to the use of an extract derived from rabbit skin inflamed by vaccinia virus in treatment. More specifically, the present invention relates to the use of an extract derived from rabbit skin inflamed by vaccinia virus in treatment of hematopoietic system damage or pancytopenia induced by cancer therapy. Furthermore, the present invention relates to the use of an extract derived from rabbit skin inflamed by vaccinia virus in treatment of leukopenia induced by cancer therapy. Furthermore, the extract derived from rabbit skin inflamed by vaccinia virus may be suitable for regeneration.

The present invention relates to recombinant Modified Vaccina Virus Ankara (MVA) encoding Epstein-Barr virus (EBV) antigens, wherein surface glycoprotein 350 (EBV gp350) and glycoprotein gH (EBV gH) are fused to subunits of self-assembling multimeric protein particle PdhC (acetyltransferase of pyruvate dehydrogenase (PDH) complex) or DPS (DNA binding protein from starved cells).

To provide newly adapted and / or more potent viruses and / or virus vectors useful for treatment of human diseases.SOLUTION: Disclosed herein is a novel immune-modulating vaccinia virus strain (IOVA) and derivatives thereof with high replication efficiency for use in the medicine. The novel vaccinia virus strain IOVA and derivatives thereof, vectors and recombinants have an ability to replicate in a mammal cancer line and being lytic or, in the case of cancer cells, oncolytic, and elicit an increased capacity to destroy cell-cycle activated cells and / or tumor cells, compared with the gold standard Vaccinia virus WR.SELECTED DRAWING: None

The present invention relates to recombinant modified vaccinia virus Ankara (MVA) encoding the spike (S) protein or portions thereof, such as the receptor binding domain (RBD), and additional antigenic sequences derived from other proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 19 (COVID-19).

The invention relates to the technical field of heat preservation boxes, in particular to vaccinia virus seed collecting and transporting equipment which comprises a box body, a support and a protective cover, a sealing plate is arranged on the box body, a sealing cover is movably connected to the box body, a protective assembly is arranged in the sealing cover, the support is arranged in the box body, and mounting blocks are arranged at the front end, the rear end, the left end and the right end of the support. During use, vaccine test tubes are conveniently fixed through the arranged fixing assembly, damage caused by shaking and collision of the vaccine test tubes in the box body is avoided, then a pull rod is pulled to drive a sliding block, a supporting plate and a protective cover to move upwards, and the matched supporting assembly supports the sliding block and the supporting plate which ascend; and then a sealing cover is covered, and the arranged protection assembly is tightly attached to the top of the vaccine test tube, so that the vaccine test tube is prevented from shaking up and down, and the protection effect on the vaccine test tube is further improved.

The disclosure provides recombinant vaccinia vectors (rVACV) comprising variant A34R proteins. As compared to a vaccinia vector comprising the wild-type A34R protein, the rVACVs described herein exhibit increased production of extra-cellular enveloped virion (EEV). Also described herein are variant A34R proteins, nucleic acids encoding variant A34R proteins, and cells containing the nucleic acids encoding variant A34R proteins. The disclosure further provides methods of producing rVACV by culturing the cells containing the nucleic acids encoding variant A34R proteins and purifying the rVACV. Furthermore, provided are methods of treating a cancer in a subject by administering to the subject rVACVs comprising the variant A34R proteins.

The invention relates to the field of biotechnology and targeted therapy, in particular to a recombinant construct, a recombinant oncolytic virus and a construction method and application of the recombinant oncolytic virus. The recombinant oncolytic virus CD19 BIKE is prepared by inserting exogenous genes of CD16 and CD19 into an oncolytic vaccinia virus genome. The antibody secreted by the recombinant virus not only can bridge NK cells and CD19 positive B cell lymphoma cells to increase contact between the NK cells and tumor cells and accumulation in tumor tissues, but also can cooperate with oncolytic viruses to dissolve tumors, break matrix barriers, remodel tumor microenvironments and improve treatment effects.

The invention belongs to the technical field of mRNA vaccine preparation, and particularly relates to a helicobacter pylori infection resistant mRNA vaccine and application thereof. A UreB antigen sequence is optimized through AI calculation, a sequence is synthesized through a gene synthesis technology after optimization, the mRNA vaccine for resisting helicobacter pylori infection is obtained through T7 in-vitro transcription, a vaccinia capping system and a lithium chloride purification mode, the mRNA vaccine can induce a body to generate T lymphocyte immune response and high-titer UreB specific antibody humoral immune response, and the helicobacter pylori infection resisting mRNA vaccine can be used for resisting helicobacter pylori infection. The composition can be used for preventing helicobacter pylori infection related diseases.

Methods and compositions are described for regulating the activity of poxvirus viral polymerase by modulating the assembly and / or interaction of one or more subunits of the viral polymerase.

The invention discloses a recombinant oncolytic vaccinia virus VV-dTVA-CD55-alphaPDL1 as well as a construction method and application thereof, three key sites of vaccinia virus genome TK, VGF and A56R are systematically knocked out through a CRISPR / Cas9 technology, a human CD55 gene and an alphaPD-L1 antibody gene are directionally inserted into the A56R site, accurate assembly of gene elements is completed through technologies such as PCR amplification, homologous recombination and seamless cloning, and the recombinant oncolytic vaccinia virus VV-dTVA-CD55-alphaPDL1 is obtained. Through verification, the recombinant virus can stably express CD55 and alphaPDL1 proteins, meanwhile, the genome stability is kept, and a research direction is provided for providing a novel biological preparation with high targeting property and high safety for treatment of malignant tumors such as colorectal cancer.

The use of extract from rabbit skin inflamed by vaccinia virus for treating Parkinson's disease or restoring neurological function of the brain or alleviating damage to neurological function of the brain in a patient suffering from Parkinson's disease is provided. The extract from rabbit skin inflamed by vaccinia virus can be Lepalvir.

The invention relates to application of a vaccinia virus inflammatory rabbit skin extract in preparation of an HPV (human papillomavirus) inhibitor.

The invention relates to the field of oncolytic vaccinia viruses, in particular to a recombinant construct, a recombinant oncolytic virus and application thereof. According to the application, the mNbTIM3 nano antibody and the hNbTIM-3 nano antibody are creatively inserted into the oncolytic vaccinia virus, so that the oncolytic vaccinia virus replicates in tumor cells and lyses the cells, and the mNbTIM-3 antibody and the hNbTIM-3 antibody are expressed while the tumor cells are killed, so that the treatment effect is improved.

The invention relates to the technical field of biology, in particular to a recombinant oncolytic vaccinia virus, a preparation method thereof and application of the recombinant oncolytic vaccinia virus in preparation of drugs for preventing or treating tumors. According to the invention, the mIL-4 is inserted into the oncolytic vaccinia virus, so that the oncolytic vaccinia virus replicates in tumor cells and lyses the cells, and the mIL-4 protein is expressed while the tumor cells are killed, thereby improving the treatment effect.

The present invention provides compositions, vaccines and methods for inducing protective immunity against an immunogen in humans. The protective immune response is obtained by using a saRNA, in particular a VRP vector as prime and a MVA for boost. Specifically, the present invention relates to genetically engineered (recombinant) VRP and MVA vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of an infectious virus such as EBV.

The application discloses a sedge plant extract with antiviral activity, a preparation method and application thereof, wherein the sedge plant is at least one of brick seed, broken rice sedge, broken joint sedge, raw fragrant cyperus, mountain bennet, one arrow ball, Jing Sanleng, water centipede, water chestnut and oil sedge beans. The sedge plant extract is obtained by alcohol extraction, water extraction or ethyl acetate extraction of the sedge plant to obtain an extract, and then the extract is dried to obtain the sedge plant extract. Experiments prove that the sedge plant extract provided by the application has significant inhibitory activity on multiple viruses such as herpes virus, vaccinia virus, adenovirus, influenza virus, coronavirus, enterovirus, respiratory syncytial virus, Zika virus, dengue virus and bunyavirus. Therefore, the sedge plant extract provided by the application can be used for preparing a pharmaceutical composition for preventing and / or treating viral infection, and can also be used for preparing health food, functional food or dietary supplements. The application has a wide application prospect.

The application relates to the field of vaccinia virus production, and provides a sterilization equipment for a vaccinia virus production workshop, which comprises a main feeding conveying belt, the rear side of the main feeding conveying belt is provided with an automatic control console, the upper surface of the main feeding conveying belt is provided with a tray mechanism, the right side of the main feeding conveying belt is provided with a cleaning mechanism, the right side of the cleaning mechanism is provided with a stacking mechanism, the right side of the stacking mechanism is provided with a steam sterilization structure, and the steam sterilization structure comprises a box mechanism, a steam mechanism and a pushing mechanism. The right side of the pushing mechanism is provided with a microwave sterilization mechanism. The automatic control console controls the cleaning mechanism, the stacking mechanism and the microwave sterilization mechanism and cooperates with the tray mechanism, so that the purpose of automatically sterilizing a batch of culture containers is achieved, the processing efficiency is improved through the automation of the equipment, and the labor burden of workers is reduced.

Provided herein is a method for efficiently capping RNA in vitro. In some embodiments the capping reaction may be done at high temperature using Vaccinia capping enzyme or a variant thereof. In other embodiments, the capping reactions may comprise a capping enzyme from a large virus of amoeba, e.g., Faustovirus, mimivirus or moumouvirus, or a variant thereof. Compositions and kits for practicing the method are also provided.

The present invention relates to a process for preparing recombinant Modified Vaccina Virus Ankara (MVA) using bacterial artificial chromosome (BAC) based permanent dominant selection.